Clinical Trials: Have We Finally Reached The New Normal?

Dec 01 2022

• By Heidi Chen

Listen to this article

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.

The COVID-19 pandemic brought acute disruption to the clinical trials landscape in 2020. While there was an explosion of trials initiated in infectious disease, clinical trials in other therapeutic areas endured setbacks in enrollment and progression. With the uptake of vaccinations from late 2020 through 2021, and the rollercoasters of variants that dashed hopes of returns to normalcy, the entire health care industry is learning to coexist with COVID-19. Clinical research, however, has adapted more quickly and early signals of recovery have translated into an impressive full-year performance in 2021. Exploring the trends within clinical trials that initiated during 2021, contrasting against pre- and peri-pandemic themes, reveals whether a post-pandemic, new normal has now been established.

According to the industry-leading clinical trial database Trialtrove, 2021 saw more than 10,000 Phase I–III clinical trials initiated for the...

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Dec 13 2022

• By Ashley Yeo

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Infographic: Top 100 Pharma Companies

Dec 13 2022

• By Lucie Ellis-Taitt

The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.

Pfizer Leads An Unusual Year For The Scrip 100

Dec 13 2022

• By Jessica Merrill

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

Dec 12 2022

• By Jo Shorthouse

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

Scrip 100: By The Numbers

Dec 06 2023

• By Lucie Ellis-Taitt and Kosh Naran

Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.